Key Points
- Exelixis EVP Dana Aftab sold 43,451 shares on May 26 for about $2.19 million at an average price of $50.35 per share. After the sale, Aftab still held 594,741 shares valued at roughly $29.95 million.
- The company recently posted stronger-than-expected quarterly results, reporting $0.87 EPS versus the $0.75 consensus and revenue of $610.81 million, up 10% year over year. Exelixis also maintained strong profitability with a 39.89% return on equity and 35.08% net margin.
- Analyst sentiment remains mixed but generally constructive, with several firms raising price targets and the stock carrying an overall “Hold” rating and average price target of $47.35. Exelixis has also drawn positive attention for upcoming investor conference appearances and improved near-term earnings estimates.
Exelixis, Inc. (NASDAQ:EXEL - Get Free Report) EVP Dana Aftab sold 43,451 shares of Exelixis stock in a transaction on Tuesday, May 26th. The shares were sold at an average price of $50.35, for a total value of $2,187,757.85. Following the completion of the sale, the executive vice president directly owned 594,741 shares of the company's stock, valued at $29,945,209.35. This trade represents a 6.81% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.
Exelixis Stock Performance
NASDAQ EXEL opened at $51.45 on Friday. The stock has a fifty day moving average of $45.83 and a 200-day moving average of $44.18. The stock has a market capitalization of $12.93 billion, a P/E ratio of 17.09, a price-to-earnings-growth ratio of 1.06 and a beta of 0.38. Exelixis, Inc. has a 52 week low of $33.76 and a 52 week high of $52.96.
Exelixis (NASDAQ:EXEL - Get Free Report) last released its earnings results on Tuesday, May 5th. The biotechnology company reported $0.87 EPS for the quarter, beating the consensus estimate of $0.75 by $0.12. Exelixis had a return on equity of 39.89% and a net margin of 35.08%.The company had revenue of $610.81 million during the quarter, compared to analysts' expectations of $607.51 million. During the same period last year, the firm earned $0.55 EPS. The business's revenue for the quarter was up 10.0% on a year-over-year basis. Equities research analysts forecast that Exelixis, Inc. will post 3.15 earnings per share for the current fiscal year.
Trending Headlines about Exelixis
Here are the key news stories impacting Exelixis this week:
- Positive Sentiment: Zacks Research raised its Q2 2026 EPS estimate for Exelixis to $0.75 from $0.72, signaling slightly better near-term earnings expectations. Zacks Research estimate update
- Positive Sentiment: Exelixis announced upcoming June fireside chats at major healthcare conferences, giving management a platform to discuss strategy and pipeline progress with investors. Investor conference webcast announcement
- Positive Sentiment: A separate article highlighted Exelixis as a profitable, cash-generative biotech that could benefit from rotation into healthcare names, which may be helping sentiment. Positive commentary on Exelixis
- Neutral Sentiment: Executive Vice President Dana Aftab sold 43,451 shares for about $2.19 million, a disclosure that can create some caution but is not necessarily a negative signal on its own. SEC insider filing
- Neutral Sentiment: Short-interest data showed no meaningful short position, so there is little evidence of a bearish squeeze setup either way. Short interest report
Wall Street Analyst Weigh In
A number of equities research analysts recently commented on the company. TD Cowen lifted their price objective on Exelixis from $51.00 to $55.00 and gave the stock a "buy" rating in a research note on Wednesday, May 6th. Zacks Research cut Exelixis from a "strong-buy" rating to a "hold" rating in a research note on Thursday, March 5th. HC Wainwright lifted their price objective on Exelixis from $54.00 to $56.00 and gave the stock a "buy" rating in a research note on Thursday, May 7th. Stifel Nicolaus lifted their price objective on Exelixis from $44.00 to $47.00 and gave the stock a "hold" rating in a research note on Wednesday, May 6th. Finally, Barclays lifted their price objective on Exelixis from $44.00 to $45.00 and gave the stock an "equal weight" rating in a research note on Monday, April 20th. One investment analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, eleven have issued a Hold rating and two have issued a Sell rating to the company's stock. According to data from MarketBeat, Exelixis currently has an average rating of "Hold" and an average price target of $47.35.
Get Our Latest Research Report on Exelixis
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. BridgePort Financial Solutions LLC bought a new stake in Exelixis in the 3rd quarter valued at $517,000. Candriam S.C.A. boosted its position in shares of Exelixis by 18.4% during the third quarter. Candriam S.C.A. now owns 696,104 shares of the biotechnology company's stock worth $28,749,000 after buying an additional 108,367 shares during the period. Dimensional Fund Advisors LP boosted its position in shares of Exelixis by 11.2% during the third quarter. Dimensional Fund Advisors LP now owns 4,180,912 shares of the biotechnology company's stock worth $172,658,000 after buying an additional 419,596 shares during the period. Allianz Asset Management GmbH boosted its position in shares of Exelixis by 153.3% during the third quarter. Allianz Asset Management GmbH now owns 2,462,948 shares of the biotechnology company's stock worth $101,720,000 after buying an additional 1,490,520 shares during the period. Finally, Illinois Municipal Retirement Fund boosted its position in shares of Exelixis by 19.1% during the third quarter. Illinois Municipal Retirement Fund now owns 204,211 shares of the biotechnology company's stock worth $8,434,000 after buying an additional 32,737 shares during the period. 85.27% of the stock is currently owned by institutional investors.
About Exelixis
(
Get Free Report)
Exelixis, Inc is a biotechnology company specializing in the discovery, development and commercialization of small molecule therapies primarily for the treatment of cancer. Building on a platform that leverages model organism genetics and high-throughput screening, the company focuses its research on kinase inhibitors that modulate critical signaling pathways involved in tumor growth and metastasis. Exelixis's translational research approach aims to advance novel compounds from early-stage discovery through clinical development and regulatory approval.
The company's most recognized products include CABOMETYX® (cabozantinib), approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma, and COMETRIQ® (cabozantinib) for metastatic medullary thyroid cancer.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
